Bimekizumab for psoriasis.
Sign Up to like & getrecommendations! Published in 2022 at "Drugs of today"
DOI: 10.1358/dot.2022.58.6.3400572
Abstract: Psoriasis is a chronic, immune-mediated, inflammatory skin disease, affecting 1% to 3% of the population in Western countries. Due to advances in the understanding of psoriasis pathogenesis, in particular, the role of the interleukin-23 (IL-23)/T-helper… read more here.
Keywords: treatment; psoriasis; bimekizumab psoriasis; bimekizumab ... See more keywords